Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Imaging of Cognition, Learning, and Memory in Aging

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Columbia University
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Yaakov Stern, Columbia University Identifier:
First received: February 14, 2011
Last updated: August 24, 2016
Last verified: August 2016

February 14, 2011
August 24, 2016
March 2011
December 2017   (final data collection date for primary outcome measure)
Cognition as measured with cognitive evaluations [ Time Frame: cross sectional ] [ Designated as safety issue: No ]
We will assess the relationship between the presence of amyloid and cognition as measured with standard cognitive and neuropsychological tests
Not Provided
Complete list of historical versions of study NCT01297114 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Imaging of Cognition, Learning, and Memory in Aging
Imaging of Cognition, Learning, and Memory in Aging
This investigation is designed to study how the brain functions when it is performing explicit memory tasks, and furthermore how the brain systems supporting performance on these tests change as a function of aging. Implicit memory tasks may be distinguished from explicit memory tests in that explicit memory characterizes the directed or intentional recollection of previously learned information or events. In contrast, implicit (or nonconscious) memory is expressed in the facilitation of performance on some task or judgment on a stimulus owing to a prior presentation of that stimulus, without any necessary conscious awareness of the prior presentation. The investigators propose to use functional Magnetic resonance Imaging (fMRI) to measure brain activity during the performance of carefully designed explicit memory tasks. Comparison of brain activity during the different test conditions will provide information about the brain areas that are involved in mediating specific aspects of performance. Both older and younger individuals will be tested in order to understand age related changes in the brain activity. In order to examine the interactions between participants' differential levels of amyloid burden and their performance on cognitive tasks and fMRI neural activation, the investigators also propose PET imaging of older participants.

The basic approach to measuring the brain activity associated with a given cognitive process (or processes) is as follows: It is known that increases in brain neuronal activity are associated with local increases in energy metabolism. Under normal circumstances, increases in brain metabolism lead to local changes in blood oxygenation in venules and larger veins. This change in blood oxygenation can be detected imaging methods which are sensitive to the differences in magnetic state between oxygenated and deoxygenated hemoglobin.

The ultimate benefit of this research is to better understand how changes in both performance and the brain organization underlying that performance are affected by aging.

Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Whole blood (frozen)
Probability Sample
Subjects will be recruited from ads placed in local newspapers and notices posted in the vicinity of Columbia University, the Columbia Presbyterian Medical Center, and in local senior centers that provide written consent for notice placement. We will also utilize a market mailing approach. Letters will be sent to appropriately aged potential subjects randomly selected from commercial lists. Additional elderly subjects will be recruited from the Sergievsky Joint Database. Informed consent will be elicited from all subjects.
Alzheimer's Disease
Drug: Florbetaben
This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
Other Name: F-18 BAY
  • Participants aged 60-70
    Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
    Intervention: Drug: Florbetaben
  • Participants aged 20-30
    Younger participants will not undergo PET scanning that will be studied with other methods.
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2021
December 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged 20-30 or 60-70
  • Residing near Columbia University Medical Center
  • Must be willing and able to participate

Exclusion Criteria:

  • Have a contraindication to PET (e.g, metallic implants, pacemaker, claustrophobia, or cannot lie flat for one hour)
  • Pregnancy
  • Lactating Women
  • Current, past, or anticipated exposure to radiation
  • Significant active physical illness
20 Years to 70 Years   (Adult, Senior)
Contact: Oksana Tatarina, MA 212-305-1987
United States
AAAB0596, R01AG026158
De-identified data could be shared based on NIH regulations
Yaakov Stern, Columbia University
Yaakov Stern
National Institute on Aging (NIA)
Principal Investigator: Yaakov Stern, PhD Columbia University
Columbia University
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP